CD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University)

N/A

Report date: 2026/02/23 20:01:44

Base Information

Drug NameCD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > mRNACell and gene therapy > Gene therapy > LNPCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacementsB-cell maturation protein modulators
TargetsB-lymphocyte antigen CD19B-cell maturation protein
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesWest China Hospital Of Sichuan University
China Registration ClassN/A

Develop Information

Active CompaniesWest China Hospital Of Sichuan University
Inactive CompaniesN/A
Active IndicationsAutoimmune Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A